Neurotech Secures $4.5 Million to Fund Pivotal Autism Trial
Neurotech International has secured $4.5 million through a share placement to fund its pivotal Phase III clinical trial of NTI164 for Autism Spectrum Disorder, aiming to reach topline data readout.
- Placement of 321 million shares at $0.014 each
- Funding to cover Phase III ASD trial and regulatory costs
- Tranche 1 settlement expected mid-August 2026
- Tranche 2 subject to shareholder approval in September
- Placement managed by Taylor Collison and Canary Capital
Capital Injection Targets Key Clinical Milestone
Neurotech International Limited (ASX:NTI) has successfully raised approximately $4.5 million through a placement of over 321 million new shares priced at 1.4 cents each. This capital boost is earmarked primarily to fund the ongoing Phase III double-blind, placebo-controlled clinical trial of NTI164 in children with Autism Spectrum Disorder (ASD), a crucial step toward potential regulatory approval and commercialisation.
Placement Structure and Timing
The placement is structured in two tranches: the first tranche, raising about $4.1 million, will settle mid-August 2026 under the company’s existing ASX listing rule capacities. The second tranche, accounting for roughly $0.4 million, awaits shareholder approval expected around September 2026. The shares issued under the placement represent a significant dilution but provide the cash runway Neurotech needs to progress through to topline data readout from the Phase III trial.
Backing from Institutional and Sophisticated Investors
Support for the placement came from both existing and new institutional and sophisticated investors, with Taylor Collison Limited and Canary Capital Pty Ltd acting as joint lead managers. Neurotech has also agreed to issue options to Taylor Collison as part of the management fee arrangement, indicating confidence in the company’s clinical development trajectory.
NTI164’s Clinical and Regulatory Progress
NTI164 is a proprietary formulation rich in CBDA and minor cannabinoids, targeting neuroinflammatory pathways implicated in neurodevelopmental disorders. The drug has already delivered statistically significant and clinically meaningful results in earlier Phase II/III trials in ASD and related paediatric neurological conditions. The current Phase III “Beyond Harmony” trial represents a critical inflection point, with topline results anticipated to shape Neurotech’s regulatory submissions and commercial prospects.
Recent regulatory milestones include FDA clearance for an Investigational New Drug application, enabling US clinical development and supporting a global registration strategy. This funding round complements prior financial arrangements, including a $3.15 million secured loan backed by R&D tax incentives, designed to sustain Neurotech’s operations through this pivotal period.
What Investors Should Watch Next
With the Phase III trial underway and cash secured through to topline data, Neurotech’s immediate focus will be on clinical execution and regulatory engagement. The shareholder vote on the second tranche of placement shares in September will be a key event, as will any updates on trial enrolment and interim data. Given the inherent uncertainties in clinical development and regulatory approval, the market will be attentive to how these milestones unfold and their impact on Neurotech’s valuation.
Bottom Line?
This capital raise positions Neurotech to navigate its critical Phase III trial phase, but success hinges on clinical outcomes and shareholder approval of the final tranche.
Questions in the middle?
- Will the shareholder meeting approve the second tranche of placement shares?
- How will topline Phase III data influence Neurotech’s regulatory pathway and partnerships?
- What are the potential timelines and hurdles for NTI164’s commercialisation?
